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Summary 
An in vitro technique has been developed for evaluating the delivery performance of topical semi-solid formulations. A thin and 
uniform layer of formulation was applied in facsimile to actual usage conditions by troweling the vehicle across a thin, circular 
copper template (200 pm in thickness). Approximately 30-45 mg of an oil-in-water cream, a water-in-oil cream or an ointment, each 
containing a range of concentrations of minoxidil, were applied over human cadaver skin within a defined circular area of 1.54 cm’. 
The rates of permeation of minoxidil from these formulations were determined by finite dose diffusion experiments. For formulations 
containing 2% minoxidil, the flux from the w/o cream tested was, about 4 times higher than fluxes from the o/w cream and the 
ointment. Even though all w/o formulations were initially saturated with drug, the flux of minoxidil from these creams increased as 
the concentration of minoxidil was increased from 0.5% to 2%. In contrast, the delivery rates from the o/w cream and the ointment 
did not appear to be dependent on the minoxidil concentration applied (OS-2%). Under the operative experimental conditions, the 
percent coefficients of variation of flux of minoxidil from these formulations were less than 20%. To achieve this low level of 
variability, the skin samples were all obtained from the same cadaver abdomen. If one assumes that the efficacy of a particular 
formulation is dependent on the ability of the drug to be released from the vehicle and diffuse through the skin, the studies show that 
the nature of the vehicle can profoundly affect delivery even when excess solid drug is present. They also indicate that reliable in vitro 
comparisons of drug delivery are possible as long as one performs the studies on skin samples taken from the same section of skin. 
Introduction 
There is an increasing emphasis on the trans- 
dermal delivery of drugs to treat systemic diseases. 
However, the majority of drugs used for topical 
administration are intended to treat local skin 
disorders. Certainly for systemic action, and in all 
likelihood for topical action as well, the efficacy of 
a particular formulation is dependent on the abil- 
ity of the drug to be released from the vehicle and 
diffuse through the skin and especially its outer- 
most layer, the stratum comeum *. The thermody- 
namic and kinetic determinants of delivery here 
are complex and attempts to evaluate the effecti- 
_ 
* The exact relationship between flux through the skin and 
delivery into the local tissues of the skin is substantially 
unresolved. Certainly when flux is high there are steeper 
concentration gradients across the living tissue. It is pre- 
sumed by us that these correlate with higher local concentra- 
tions and greater efficacy at the local level, but this remains 
unproven. 
Correspondence: N.D. Weiner, College of Pharmacy, Univer- 
sity of Michigan, Ann Arbor, MI 48109, U.S.A. 
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veness of various formulations by in vitro methods 
have generally been unsuccessful. One problem is 
that there is no well developed experimental tech- 
nique to apply finite doses as thin films in facsi- 
mile to the usage situation. Thus, although the 
necessity of having an in vitro method to correlate 
with the in vivo studies is recognized, there is no 
simple and generally accepted technique to sort 
out the performance of formulations effectively 
(Guy et al. 1986). 
The purpose of this study is to demonstrate 
that the relative drug delivery merits of topical, 
semi-solid dosage forms can be sorted out using in 
vitro diffusion cell techniques as has been conjec- 
tured earlier by Addicks et al. (1987) based on 
studies involving synthetic membranes. This ap- 
proach involves the application of a thin and 
uniform film of formulation to human cadaver 
skin and determination of fluxes of a given drug 
by finite dose diffusion experiments. The test 
compound chosen for the studies was minoxidil, 
which has been shown to be of some benefit in the 
treatment of alopecia areata when applied topi- 
cally (Weiss et al., 1981). The procedures were 
developed as part of our mission to establish a 
standard method to evaluate the performance of 
semi-solid topical formulations. 
Materials and Methods 
Materials 
Minoxidil, USP milled, was supplied by The 
Upjohn Co. (Kalamazoo, MI). The [piperidine- 
3H]minoxidil was obtained from the same source 
with a radiochemical purity of 98% and a spec. 
act. of 25 Ci/mmol. The various vehicle compo- 
nents, namely, mineral oil (Mallinkrodt, Paris, KY) 
Carbopol 940 (BF Goodrich, Cleveland, OH). 
Quadrol polyol (BASF Corp., Chemical Div., 
Parsippany, NJ), Tween 60, Arlacel 60, Arlacel 83 
(ICI Americas, Wilmington, DE), white petro- 
latum (CMC, Smyrna, TN) and white wax were 
used as received. 
Preparation of minoxidil formulations 
A recrystallized mixture of radiolabelled and 
cold minoxidil was prepared by the following pro- 
TABLE 1 
Formulue for each of the mnoxidil-containing uehlcles tested 
Component Parts by weight 
o/w Cream w/o Cream Ointment 
White petrolatum - 45 50 
White wax _ 2 5 
Mineral oil 20 45 
Tween 60 2.8 _ 
Arlacel60 2.2 1 
Arlacel 83 _ 3 _ 
Water 75 50 _ 
Carbopol940 0.3 _ _ 
Quadrol q.s. _ 
cedure. [3H]minoxidil stock solution in methanol 
(about 0.3 mCi in 300 ~1) was placed in a 100 ml 
flask and dried under nitrogen. The dried radio- 
labelled rninoxidil was mixed together with about 
100 mg of unlabeled minoxidil and 4 ml warm 
ethanol were added to dissolve the mixture. About 
80 ml hexane were then added to initiate recrys- 
tallization of the minoxidil. The flask was chilled 
in an ice bath for 4 h and the recrystallized 
minoxidil powder was collected under vacuum 
and placed in a desiccator overnight to facilitate 
removal of the solvents. The specific activity of 
the recrystallized minoxidil was determined to be 
4-5.6 pCi/mg. Since the amount of radiolabelled 
minoxidil available was limited, 0.5%, 1% and 2% 
minoxidil formulations were prepared by incorpo- 
rating a suitable amount of the recrystallized 
minoxidil into approximately 400 mg of each of 
three vehicles (Table 1) contained on a watch glass 
with the aid of a small pestle. 
Application of formulation 
To establish the technique for applying thin 
reproducible films of each formulation onto the 
skin, the following was done. First, a piece of 
Parafilm (American Can Co., Greenwich, CT) with 
size of about 4 cm2 was cut and weighed. A 
template (200 pm thick, brass disc of diameter 3.1 
cm with a hole of diameter 1.4 cm cut in the 
center) was then put on top of the Parafilm. The 
formulation was applied to the surface of the 
Parafilm and troweled flush with the edge of the 
template with the aid of a cover glass. The tem- 
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plate was carefully removed and the Parafilm con- 
taining the formulation was again weighed. The 
net weight of the formulation applied on the 
Parafilm was determined from the difference be- 
tween the two measurements. An evaluation of the 
technique for applying thin films to human cadaver 
skin was also done. 
To prepare the skin membrane, skin samples 
(about 200 pm in thickness) were taken with a 
dermatome from a single cadaver donor. These 
were placed in the freezing compartment of a 
standard laboratory refrigerator and frozen at the 
temperature of the compartment; - 20 o C. Tissue 
was kept frozen at this temperature until an ex- 
periment was begun. Portions of the frozen skin 
were thawed before use and appropriate-sized sec- 
tions of the skin (4 cm*) were cut and put on a 
larger piece of Parafilm with the stratum corneum 
facing upward. The weight of the skin sample was 
then determined. The residual dermis was not 
separated from the dermatomed skin sample since 
preliminary results had shown that the flux of 
minoxidil through the separated epidermis was no 
different than through the dermatomed skin. The 
formulation was applied to the surface of the skin 
as described and the weight was measured. The 
net weight of the formulation applied on the skin 
was found from the difference between the two 
weight measurements. 
Permeation studies 
The abdominal skin of a deceased 85 years old 
white female was used for the permeation experi- 
ments. After the minoxidil formulation was ap- 
plied to the skin membrane with formulation fac- 
ing upward, the tissue was mounted in a Franz 
diffusion cell (Crown Glass, Somerville, NJ). For- 
mulation was applied to a skin section and the 
section was mounted in a diffusion cell in one 
continuous operation; only a minute or two 
elapsed from the actual application to initation of 
a run. The receiver compartment was maintained 
at 37 o C with circulating water. The reservoir con- 
tained phosphate buffer (pH 7) and was stirred 
with a bar magnet. The phosphate buffer was 
equilibrated to 37OC before the start of the ex- 
periments and the receiver compartment was par- 
tially filled with the buffer. After assembling the 
diffusion cells, phosphate buffer was added to the 
receiver compartment to a predetermined level. 
The moment of mounting the membrane on a 
Franz cell was defined as the “zero time” for each 
run. At predetermined time intervals samples were 
withdrawn from the receiver compartment by a 1 
ml tuberculin syringe with a 23-gauge needle fitted 
with a section of PE-50 polyethylene tubing. Each 
volume removed for sampling was replaced with 
an equal volume of phosphate buffer. Exactly 0.5 
ml of each sample were pipetted into 10 ml liquid 
scintillation fluid (Safety Solve, RPI, Mount Pros- 
pect, IL) and assayed on a scintillation counter. 
Analysis of data 
After correcting concentrations for dilution as- 
sociated with repetitive sampling, the concentra- 
tion data were plotted as the cumulative amount 
collected in the receiver compartment as a func- 
tion of time. The flux of minoxidil per unit area of 
membrane into the reveiving reservoir in the 
quasi-steady state is equal to: 
JJ! 5% 
A ’ dt 
where J is the per unit area pseudo-steady-state 
flux (mg/cm2/h) across the skin; A is the area for 
diffusion (cm*); V is the volume of the receiver 
compartment (ml); and dC/dt is the steady-state 
slope (mg/ml/h). 
Results 
The weights for the applications of the 3 formu- 
lations and the reproducibility resulting from the 
procedure used to apply the formulations as uni- 
form thin films over Parafilm are indicated in 
Table 2. The average weights of applications over 
human cadaver skin concur with those placed over 
Parafilm (Table 2), essentially showing that the 
nature of the membrane presented no major diffi- 
culties in spreading the films. Moreover, it was 
found that the creams and ointment could be 
applied to either of these surfaces reproducibly, 
with the percent coefficient of variation generally 
less than 15%. This was considered adequate re- 
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TABLE 2 
Weight of formulations applied on Parafilm and on human 
cadaver skin with a copper template (1.54 cm2 in area and 200 
pm in thickness 
Sample no. Weight (mg) applied on parafilm 












Avg. + SD. 
Avg. f S.D. 
40.3 26.8 24.1 
53.3 38.0 37.3 
45.8 36.5 33.1 
42.8 30.9 30.5 
41.0 30.0 28.5 
40.8 29.6 21.1 
_ 21.7 24.4 
_ 21.1 _ 
51.8 36.5 37.3 
43.2 31.1 31.4 
41.9 30.1 30.2 
44.5 + 4.8 30.2k5.5 30.6 k 4.5 
Weight (mg) applied on human cadaver skin 
48.6 _ 31.4 
50.0 _ 31.6 
40.5 _ 26.1 
31.5 _ 25.6 
48.5 _ 26.1 
35.4 _ 22.9 
_ 22.2 
43.4 f 6.4 26.6 * 3.1 
producibility for the research purposes. Repre- 
sentative plots of fluxes of 2% of minoxidil from 
the various formulations tested are shown in Fig. 
1. The fluxes of minoxidil as a function of 
minoxidil concentration from the 3 formulations 
are summarized in Table 3. 
Discussion 
In vitro methods involving determination of the 
rate and extent of penetration of an applied drug 
through the skin are often employed to assess 
topical drug delivery. Altough many approaches 
have been tried, there is no generally accepted 
technique to evaluate the kinetics of delivery of 
drugs from dermatological formulations. Rather, 
the majority of studies associated with the devel- 
opment of topical drugs have dealt with the innate 
permeation of a given drug or a family of analogs. 
Most have not recognized and addressed the fact 
that interactions which modulate drug delivery 
exist between the drug, its vehicle and the skin. As 
a result, formulation effects are generally not well 
understood. Furthermore, while many studies are 
conducted that employ synthetic membranes or 
animal skin membranes as model systems to pre- 
dict the in vivo clinical situation, there is some 
evidence that vehicle-skin and drug-skin interac- 
tions are species-dependent and human skin re- 
sponds in ways unpredictable from studies involv- 
ing animal skin tissue and “model membranes”. 
Finally, existing in vitro techniques generally fail 
to deal realistically with the amount of topical 
media actually applied to the skin surface. 
The in vitro technique described here is our 
first attempt to evolve a method for evaluating the 
in vivo performance of semi-solid formulations for 
topical drug delivery. Human cadaver skin pre- 
pared in thin sheets with the aid of a dermatome 
was used to avoid species-dependent effects on 
delivery. To eliminate high inter-subject and 
intra-subject skin variations reported by other re- 
search groups (Langguth et al., 1986; Southwell et 
al., 1984) an abdominal section from a single 
human cadaver was used for all experiments. 
Since the thickness of a formulation theoreti- 
cally affects the release of a drug from a given 
formulation (Flynn et al., 1985; Guy and Hadgraft, 
1980) thin layers of the formulations were applied 
to the skin instead of infinitely thick slabs. This 
was achieved by using a 200 pm thick copper 
TABLE 3 
Fluxes of minoxidil from different formulations through human 
cadaver skin determined by finite dose experiments. The diffu- 
sional area of the skin for all the experiments was 1.54 cm2 
Values given are mean f S.D. with number of experiments 
given in parentheses. 
Minoxidil Minoxidil flux (mg/h/cm* x 104) 
cont. 
w (w/w) 
w/o Cream o/w Cream Ointment 
0.5 1.4*0.1 (3) 0.40* 0.10 (3) 0.75 +0.13 (3) 
1.0 2.1*0.3 (3) 0.34 + 0.04 (3) - 






Fig. 1. Representative plots of permeation of 2% minoxidil from various vehicles through human cadaver skin by finite dose 
experiments. The diffusional area of the skin for all the experiments was 1.54 cm*. 
template as a mold. Troweling the formulation 
across the template results in highly reproducible 
films (Table 2) with coefficients of variation of the 
weights of these applications typically being 
lo-15%. Based on the density of each formulation 
(0.85, 0.83, 0.89 for ointment, w/o cream and o/w 
cream, respectively), the applied thickness of oint- 
ment, w/o cream and o/w cream are estimated as 
234 k 35, 348 + 38 and 223 & 62 pm, respectively. 
The estimated thicknesses of the o/w cream and 
ointment film relate well to the thickness of the 
template (200 pm) while the estimated thickness 
of w/o cream appears half again thicker than the 
depth of the well of the template. We are unable 
to offer a satisfying reason why the latter films 
weigh 50% more than anticipated. 
Representative plots of permeation of minoxi- 
dil from the 2% o/w cream, the w/o cream and 
the ointment (Fig. 1) indicate that minoxidil accu- 
mulates at a steady rate in the receiver compart- 
ment after an initial lag period. The achievement 
of steady-state was not unexpected since minoxidil 
was present in each of the formulations in amounts 
exceeding its solubility. The slope of the steady- 
state line was used to calculate flux values of 
minoxidil from the various formulations. 
An exarniniation of Table 2 points out two 
important effects of the formulation on the flux of 
minoxidil through the skin. Firstly, the w/o cream 
is clearly the superior formulation with respect to 
minoxidil transport. It delivers more minoxidil per 
unit time (even at 0.5%) than the other two formu- 
lations. Whereas this is apparent at all rninoxidil 
concentrations tested, it is most evident at the 2% 
concentration level (P -C 0.01). Of considerable 
further interest, the w/o formulation showed a 
significant concentration dependence with respect 
to the delivery’ of minoxidil (e.g. P < 0.01 for the 
2% cream vs the 0.5% cream). Minoxidil is present 
as suspended matter at each of the concentrations 
tested and thus there is no reason to suspect that 
this formula is affecting the barrier properties of 
the skin in some proportion to the amount of 
minoxidil applied. Therefore, the concentration 
dependency appears to be a clear demonstration 
of a circumstance where the kinetics of solubiliza- 
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tion and diffusion in the vehicle have a major 
influence on the rate of delivery. This concentra- 
tion dependence could be due to more rapid dis- 
solution of drug from the higher concentration 
formulations as a result of greater surface area of 
the suspended particulates. Exactly how the 
evaporation of the internal water phase affects the 
kinetics is obscure but it may be a contributing 
factor. Perhaps more important than the individ- 
ual differences in the delivery from the formula- 
tions in this study is the fact that such differences 
can in fact be demonstrated when great care is 
taken to define the experimental system and pro- 
tocol used. 
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